Know Cancer

or
forgot password

Longitudinal, Randomized, Open and Prospective Clinical Trial to Evaluate the Efficacy of Continuous vs Intermittent Maximum Androgen Blockade (CMAB vs IMAB) With Goserelin-Bicalutamide Combination in the Treatment of Hormonal naïve With Metastatic Prostate Cancer


Phase 4
18 Years
N/A
Not Enrolling
Male
Metastatic Prostate Cancer

Thank you

Trial Information

Longitudinal, Randomized, Open and Prospective Clinical Trial to Evaluate the Efficacy of Continuous vs Intermittent Maximum Androgen Blockade (CMAB vs IMAB) With Goserelin-Bicalutamide Combination in the Treatment of Hormonal naïve With Metastatic Prostate Cancer


Inclusion Criteria:



- Histological diagnosis of D2 of Adenocarcinoma,

- Naivety to treatment

- Valuable bone metastasis

Exclusion Criteria:

- Hematological, liver or renal toxicity Grade IV

- Severe and active infections

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Time to progression

Principal Investigator

AstraZeneca Mexico Medical Director, MD

Investigator Role:

Study Director

Investigator Affiliation:

AstraZeneca

Authority:

Mexico: Ministry of Health

Study ID:

D6876L00010

NCT ID:

NCT00255268

Start Date:

August 2004

Completion Date:

Related Keywords:

  • Metastatic Prostate Cancer
  • Prostatic Neoplasms

Name

Location